(firstQuint)Study to Evaluate QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.

2991+1655A>G Mutation (p.

Cys998X) in the CEP290 Gene.

 The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.

Cys998X mutation.

 Subjects will receive QR-110 in one eye every 3 months, for a maximum of 4 doses.

 Up to 3 dose levels of QR-110 will be evaluated.

.

 Study to Evaluate QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.

2991+1655A>G Mutation (p.

Cys998X) in the CEP290 Gene@highlight

The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.

Cys998X mutation.

